Camilla Oliveira Hoff

Ms. Camilla Oliveira Hoff

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JMJoao Manzi
Joao Manzi
CHCamilla Oliveira Hoff
Camilla Oliveira Hoff
RFRaphaella De Paula Ferreira
Raphaella De Paula Ferreira
APAgustin Pimentel
Agustin Pimentel
JDJashodeep Datta
Jashodeep Datta
PAPhillipe Abreu
Phillipe Abreu
In 2022, approximately 600,000 cancer deaths were expected; more than 50,000 of those deaths would be from colorectal cancer (CRC). The CRC mortality rate in the US has decreased in recent decades, with a 51% drop between 1976 and 2014. This drop is attributed, in part, to the tremendous therapeutic improvements, especially after the 2000s, in addition to increased social awareness regarding risk factors and diagnostic improvement. Five-fluorouracil, irinotecan, capecitabine, and later oxaliplatin were the mainstays of mCRC treatment from the 1960s to 2002. Since then, more than a dozen drugs have been approved for the disease, betting on a new chapter in medicine, precision oncology, which uses patient and tumor characteristics to guide the therapeutic choice. Thus, this review will summarize the current literature on targeted therapies, highlighting the molecular biomarkers involved and their pathways.

1 December 2021 in JCO Global Oncology
Verified
Journal Article
Open access
NGNader Marta Guilherme
Nader Marta Guilherme
RBRenata Colombo Bonadio
Renata Colombo Bonadio
OSOdeli Nicole Encinas Sejas
Odeli Nicole Encinas Sejas
GWGabriel Watarai
Gabriel Watarai
MMMaria Cecilia Mathias Machado
Maria Cecilia Mathias Machado
PHPaulo M. Hoff
Paulo M. Hoff
PURPOSE: Patients with cancer are at increased risk for unfavorable outcomes from COVID-19. Knowledge about the outcome determinants of severe acute respiratory syndrome coronavirus 2 infection in this population is essential for risk stratification and definition of appropriate management. Our objective was to evaluate prognostic factors for all-cause mortality in patients diagnosed with both cancer and COVID-19. METHODS: All consecutive patients with cancer hospitalized at our institution with COVID-19 were included. Electronic medical records were reviewed for clinical and laboratory characteristics potentially associated with outcomes. RESULTS: Five hundred seventy-six consecutive patients with cancer and COVID-19 were included in the present study. An overall in-hospital mortality rate of 49.3% was demonstrated. Clinical factors associated with increased risk of death because of COVID-19 were age over 65 years, Eastern Cooperative Oncology Group performance status > 0 zero, best supportive care, primary lung cancer, and the presence of lung metastases. Laboratory findings associated with a higher risk of unfavorable outcomes were neutrophilia, lymphopenia, and elevated levels of D-dimer, creatinine, C-reactive protein, or AST. CONCLUSION: A high mortality rate in patients with cancer who were diagnosed with COVID-19 was demonstrated in the present study, emphasizing the need for close surveillance in this group of patients, especially in those with unfavorable prognostic characteristics.

12 November 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
KCKevin J. Contrera
Kevin J. Contrera
RFRenata Ferrarotto
Renata Ferrarotto
BGBrandon Gunn
Brandon Gunn
SSShirley Y. Su
Shirley Y. Su
MKMerrill S. Kies
Merrill S. Kies
EHEhab Y Hanna
Ehab Y Hanna
Purpose: Outcomes after primary surgery for advanced sinonasal squamous cell carcinoma (SCC) are poor. We tested whether induction chemotherapy (IC) can improve disease control or organ preservation. Patients and Methods: A phase II trial evaluated previously untreated patients with stage II to IV, M0 sinonasal SCC. Patients received IC with docetaxel, cisplatin, and fluorouracil, followed by chemoradiotherapy (CRT) for responders and surgery with adjuvant radiotherapy or CRT for nonresponders. The primary endpoints were overall response rate and locoregional control. Secondary endpoints included progression-free survival (PFS), overall survival (OS), organ preservation, and treatment toxicity. Results: Of the 31 patients enrolled between 2008 and 2020, 28 were evaluated for efficacy. Disease was T4a, T4b, and N+ in 57%, 21%, and 36% of patients, respectively. The overall response rate was 82.1%; 17.9% of patients had stable disease, and 0% had progressive disease. Grade 3 and 4 adverse events occurred in 54% and 18% of patients, respectively; there were no grade 5 adverse events. The 2-year locoregional control and PFS rates were 64.3% [95% confidence interval (CI), 40.4–77.6) and 52.4% (95% CI, 32.3–69.0), respectively. The median PFS was 25.8 months. The median OS was 47.4 months, with a 2-year OS rate of 69.4% (95% CI, 44.9–80.4). No survival difference was observed between surgery versus CRT (HR, 1.07; 95% CI, 0.9–3.84). Of patients alive at 2 years, 63% achieved organ preservation, avoiding maxillectomy (38%), craniotomy (13%), or orbital exenteration (38%). Conclusions: IC and response-directed local treatment achieved promising disease control and added organ preservation for patients with advanced sinonasal SCC.

13 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JMJoao Manzi
Joao Manzi
CHCamilla Oliveira Hoff
Camilla Oliveira Hoff
RFRaphaella De Paula Ferreira
Raphaella De Paula Ferreira
RPRenata Ponsirenas
Renata Ponsirenas
GSGennaro Selvaggi
Gennaro Selvaggi
PAPhillipe Abreu
Phillipe Abreu
The liver is the world’s sixth most common primary tumor site, responsible for approximately 5% of all cancers and over 8% of cancer-related deaths. Hepatocellular carcinoma (HCC) is the predominant type of liver cancer, accounting for approximately 75% of all primary liver tumors. A major therapeutic tool for this disease is liver transplantation. Two of the most significant issues in treating HCC are tumor recurrence and graft rejection. Currently, the detection and monitoring of HCC recurrence and graft rejection mainly consist of imaging methods, tissue biopsies, and alpha-fetoprotein (AFP) follow-up. However, they have limited accuracy and precision. One of the many possible components of cfDNA is circulating tumor DNA (ctDNA), which is cfDNA derived from tumor cells. Another important component in transplantation is donor-derived cfDNA (dd-cfDNA), derived from donor tissue. All the components of cfDNA can be analyzed in blood samples as liquid biopsies. These can play a role in determining prognosis, tumor recurrence, and graft rejection, assisting in an overall manner in clinical decision-making in the treatment of HCC.

15 May 2025 in Cancer
Verified
Journal Article
Open access
CHCamilla Oliveira Hoff
Camilla Oliveira Hoff
LFLei Feng
Lei Feng
FBFlavia Bonini
Flavia Bonini
LSLuana G. Sousa
Luana G. Sousa
KWKaiwen Wang
Kaiwen Wang
RFRenata Ferrarotto
Renata Ferrarotto
Background: Adenoid cystic carcinoma (ACC) frequently has pulmonary metastasis (PM). Given limited systemic therapy options, these metastases are often treated with pulmonary metastasis–directed local therapy (PM‐LT), although with unknown impact on overall survival (OS). This single institution, retrospective cohort study investigated the survival outcomes of PM‐LT versus no PM‐LT in ACC.Methods: ACC patients with at least one PM (≥5 mm) were included. PM‐LT was metastasectomy or radiotherapy. Clinicopathologic characteristics were compared between patients with and without PM‐LT. Primary end point was OS from PM diagnosis, with landmark analysis at 6 months, 1 year, 2 years, and 3 years after metastasis diagnosis, with Cox proportional hazards model multivariate analysis and propensity score matching analysis. Subgroup analysis by ACC histology (solid/nonsolid) was performed.Results: Of 219 included ACC, 119 (54%) had no PM‐LT and 100 (46%) did. PM‐LT patients had more nonsolid histology (p = .0008), oligometastases (p < .0001), exclusively PM (p = .02), and longer time to metastasis from diagnosis (p < .0001). On univariate analysis, PM‐LT by 6 months, 1 year, and 2 years, but not by 3 years, increased OS. On multivariate analysis, PM‐LT by 6 months (p = .12), 1 year (p = .08), or 3 years (p = .08) did not significantly increase OS, but PM‐LT by 2‐years had a borderline statistically significant association (p = .045). Of the 104 nonsolid ACC, 50 underwent PM‐LT and 54 did not. On univariate and multivariate analysis, PM‐LT did not increase OS at any time point for nonsolid ACC.Conclusion: This is the largest study of survival outcomes of PM‐LT in metastatic ACC. Findings suggest PM‐LT does not increase OS in unselected ACC.

1 April 2024 in JCO Precision Oncology
Verified
Journal Article
Open access
CHCamilla Oliveira Hoff
Camilla Oliveira Hoff
ELEduardo Andreazza Dal Lago
Eduardo Andreazza Dal Lago
JSJuliana Mota Siqueira
Juliana Mota Siqueira
LSLuana G. de Sousa
Luana G. de Sousa
AEAdel K. El-Naggar
Adel K. El-Naggar
RFRenata Ferrarotto
Renata Ferrarotto
First use of AXL-targeting in adenoid cystic carcinoma (ACC); with positive results, ACC now included in AXL studies.